Expertise in
10
conditions

Aleix Prat

Barcelona, CT, ES 
Expertise in
10
conditions
Barcelona, CT, ES 

Overview

Aleix Prat practices practicing medicine in Barcelona, Spain.

Mr. Prat is highly rated in 10 conditions, according to our data. His clinical expertise encompasses HER-2 Positive Breast Cancer, Breast Cancer, PIK3CA-Related Overgrowth Spectrum, Mastectomy, and Endoscopy.

He is actively involved in clinical research, co-authoring 238 peer reviewed articles and participating in 2 clinical trials.

Gender

Male

Locations

Barcelona, CT, Spain
Other Locations
Pi, CT, Spain
Spain
Badalona, CT, Spain

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Experts who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

2 Clinical Trials

A Window-of-opportunity Study of U3-1402, a HER3-targeting Antibody-drug Conjugate in Operable Breast Cancer According to ERBB3 Expression
A Window-of-opportunity Study of U3-1402, a HER3-targeting Antibody-drug Conjugate in Operable Breast Cancer According to ERBB3 Expression
Enrollment Status: Unknown
Publish Date: June 23, 2023
Intervention Type: Drug
Study Drug: U3 1402
Study Phase: Early Phase 1
A Randomized Multicenter Pivotal Study of CDX-011 (CR011-vcMMAE)in Patients With Metastatic, gpNMB Over-Expressing, Triple Negative Breast Cancer (The METRIC Study)
A Randomized Multicenter Pivotal Study of CDX-011 (CR011-vcMMAE)in Patients With Metastatic, gpNMB Over-Expressing, Triple Negative Breast Cancer (The METRIC Study)
Enrollment Status: Completed
Publish Date: March 08, 2019
Intervention Type: Drug
Study Phase: Phase 2
View 1 Less Clinical Trial

238 Total Publications

Pathologic Complete Response (pCR) Rate and Predictors of Response to Taxane, Trastuzumab, and Pertuzumab in HER2‑Positive Breast Cancer: Secondary Analyses of EA1181/CompassHER2 pCR.
Pathologic Complete Response (pCR) Rate and Predictors of Response to Taxane, Trastuzumab, and Pertuzumab in HER2‑Positive Breast Cancer: Secondary Analyses of EA1181/CompassHER2 pCR.
Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology
Published: August 20, 2026

Frequently Asked Questions about Aleix Prat

Is Aleix Prat a top-rated expert for HER-2 Positive Breast Cancer?

MediFind is an objective health platform that identifies experts based on real-world data. Aleix Prat is classified as an Elite expert for HER-2 Positive Breast Cancer, meaning they are among the top experts in the country for this condition. This ranking is based on their volume of patients, published research, and peer connections.

Does Aleix Prat participate in research or clinical trials?

Yes. Aleix Prat has published 238 articles and abstracts on conditions like HER-2 Positive Breast Cancer. You can view a list of Aleix Prat's latest peer-reviewed publications and clinical trial participation on their profile to see if they are active in new treatments.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Mr. Prat's expertise for a condition
ConditionClose
View All 26 Experienced Conditions
Want to save this expert for later?
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
 
 
 
 
Learn about our expert tiers
Learn More
Are you the provider on this profile?
Claim Profile